ASX Health Stocks: Immuron chalks up record half for travelers’ diarrhoea medicine, Travelan
Health & Biotech
Health & Biotech
Immuron (ASX:IMC) rose by almost 3% this morning after reporting record half yearly sales for its flagship product, Travelan.
For H1 FY24, sales of Travelan increased to $1.85m, compared to $1.05m in the pcp. The figure was also 132% higher than the pre-pandemic peak period of H1, FY20.
This increase partially reflects the three months (May, June, July) of back orders accrued while the company awaited GMP clearance from the TGA.
Travelan is an orally administered immunotherapy that reduces the likelihood of contracting travelers’ diarrhoea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce.
In the US, sales of Travelan for H1 FY24 were $482k, compared to $295k in H1 FY23.
Immuron previously reported that it had shipped inventory to Amazon for launch in US. The Amazon launch continues to progress well with sales ahead of budget.
As we are now entering the low travel season in US, Immuron anticipates sales to grow strongly closer to the peak spring/summer travel period.
The maternity care health tech company, HeraMED (ASX:HMD), announced a strategic collaboration agreement with South Australia’s GPEx, an organisation that delivers solutions for primary care, including GP shared care programs and clinical trials.
GPEx and HeraMED will be undertaking a pilot program to better understand how the HeraCARE platform can benefit pregnant mothers and the health industry, in regional and remote South Australia.
Under the terms, both companies will evaluate the deployment of the HeraCARE digital monitoring and management platform in high-risk pregnancies in regional and remote South Australia.
The aim is to ultimately improve outcomes, decrease face-to-face antenatal visits, and ease the burden on the health system.
The HeraCARE system allows expectant mothers to measure vitals at home via a mobile app and several smart connected devices, including a foetal heart rate monitor, blood pressure and glucometer.
Doctors could then remotely monitor the mother and baby via a dashboard, identifying early complications and providing increased peace of mind during pregnancy.
PharmAust (ASX:PAA) meanwhile has partnered with leading MND/ALS clinical study design and statistical analysis specialists, Berry Consultants.
US-based Berry Consultants has a strong track record in clinical trial design and experience with the FDA.
Their resume includes participation in the advisory committee meeting for the recent US FDA accelerated approval of Amylyx Pharmaceutical’s Relyvrio for MND/ALS. They’ve also been integral to the Healey ALS Platform Trial.
Under the partnership deal, Berry Consultants will oversee the design of PharmAust’s adaptive Phase 2/3 study to best position monepantel for FDA approval for the treatment of MND/ALS.
At Stockhead we tell it like it is. While PharmAust is a Stockhead advertiser, it did not sponsor this article.